Literature DB >> 28843384

Staging of recent HIV-1 infection using Geenius rapid confirmatory assay compared to INNO-LIA, New Lav and Blot 2.2 assays.

E Tuaillon1, A Sanosyan2, A Pisoni3, J Liscouët2, A Makinson4, P Van de Perre3.   

Abstract

BACKGROUND: Besides confirmation of HIV seropositivity, Western Blot (WB) assays play an important role for identification of recent infection based on incomplete antibody reactivity and lack of p31 band.
OBJECTIVES: We evaluated the capacities of the Geenius™ HIV1/2 Confirmatory Assay (Bio-Rad), a new generation rapid confirmatory assay based on immune-chromatography and automated reading, for staging of HIV-1 infection. STUDY
DESIGN: Sixteen samples collected during early HIV-1 infections (Fiebig stage III-VI) were tested using the Geenius assay, and compared to HIV Blot 2.2 WB assay (MP Diagnostics), New Lav Blot I WB assay (Bio-Rad) and INNO-LIA™ HIV I/II Score Dot Blot assay (Fujirebio). Results obtained with Geenius and INNO LIA in 47 newly diagnosed chronic HIV-1 infections were also compared.
RESULTS: The p24 band was less frequently detected in early HIV-1 infections using the Geenius (3/16) compared to the New Lav (15/16, p<0.0001), INNO-LIA (13/16, p=0.0011), and Blot 2.2 (13/16, p=0.0011). Testing samples collected during chronic infection allowed to confirm that p31 band and complete Gag, Pol, Env profiles were less frequently observed using the Geenius assay compared to the INNO LIA assay (p=0.027 for p31, and p=0.0015 for complete profile).
CONCLUSIONS: The Geenius assay is a simple and rapid test showing a high sensitivity to detect Env bands and to confirm HIV-1 seropositivity during the early phases of infection. However, this test is less suitable for distinguishing between later stages of acute and chronic infections because of a reduced sensitivity to detect the p31 and p24 bands compared to INNO LIA and New Lav assays.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Early HIV infection; Geenius assay; HIV diagnosis; Western Blot; acute HIV infection

Mesh:

Substances:

Year:  2017        PMID: 28843384     DOI: 10.1016/j.jcv.2017.08.003

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  5 in total

1.  Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China.

Authors:  Shouli Wu; Min Gao; Jian Zheng; Pingping Yan; Wei Wang; Xiaoli Lu; Yuefeng Qiu; Yansheng Yan
Journal:  Virol Sin       Date:  2019-06-12       Impact factor: 4.327

2.  Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.

Authors:  Mark M Manak; Linda L Jagodzinski; Ashley Shutt; Jennifer A Malia; Mike Leos; Jason Ouellette; Siriwat Akapirat; Donn L Colby; Nittaya Phanuphak; Leigh Anne Eller; Merlin L Robb; Mark de Souza; Jintanat Ananworanich; Sheila A Peel
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

3.  Difficulties of Identifying the Early HIV Antibody Seroconversion Period Depending on the Confirmatory Assay.

Authors:  Karl Stefic; Nadia Mahjoub; Céline Desouche; Marie Laure Néré; Damien Thierry; Constance Delaugerre; Francis Barin; Marie Laure Chaix
Journal:  Open Forum Infect Dis       Date:  2020-04-21       Impact factor: 3.835

4.  Performance of the HIV Blot 2.2, INNO-LIA HIV I/II Score, and Geenius HIV 1/2 Confirmatory Assay for use in HIV confirmation.

Authors:  Chui Ching Wong; Siew Hoon Lim; Chai Teng Tan; Sook Yin Lui; Yee Leng Lee; Kwai Peng Chan
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

5.  Evaluation of the Bio-Rad Geenius HIV 1/2 Assay as Part of a Confirmatory HIV Testing Strategy for Quebec, Canada: Comparison with Western Blot and Inno-Lia Assays.

Authors:  Bouchra Serhir; Céline Desjardins; Florence Doualla-Bell; Marc Simard; Cécile Tremblay; Jean Longtin
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.